# RE:CM GLOBAL Fund (Class B)

Period ended 31 August 2013



Portfolio Manager Daniel Malan, Wilhelm Hertzog, Paul Whitburn

SectorGlobal EquityInception Date14 Dec 2010Total Fund SizeUS \$491.6 millionFund Size (Class B)US \$45.2 millionBenchmarkMSCI World Index

Fund Status Open
Initial Fee No initial fee
Annual Fee (Class B) 1.0% annual fee
Hurdle Rate MSCI World + 2.5%

Performance Fee 20% above/below hurdle rate

Pricing Frequency Daily

Administrators Kleinwort Benson Domicile Guernsey

Total Expense Ratio 1.35% Income Declarations None

Regulation 28 Does not comply

### About the Fund

The RE:CM Global Fund is a US dollar denominated equity-centric fund domiciled in Guernsey. It invests predominantly in large global companies listed on recognised exchanges across all markets. A prospectus is available from RE:CM Collective Investments (Pty) Ltd.

#### **Fund Objective**

The portfolio aims to outperform the MSCI World Index in USD (including income) over the long term with lower than average risk of capital loss and with less volatility than the index.

### **Risk Measures**

Whilst the risk is higher than that of a global balanced fund, our investment process is designed to minimise the risk of losing money over the long term.

### **RISK STATISTICS AND PORTFOLIO DETAIL**

# **FUND RISK PROFILE**

			<b>✓</b>	
LOW	LOW-MODERATE	MODERATE	MODERATE-HIGH	HIGH

### **TOP HOLDINGS (%)**


August 2013					
Amplats	5.9	Ultra Petroleum	3.9		
Ichirizuka Master Fund	5.2	Intel	3.8		
Carrefour	5.0	Impala Platinum	3.3		
Microsoft	4.9	Sonae	3.2		
Arcelor Mittal	4.4	BP	3.2		

### **GEOGRAPHICAL ALLOCATION (%)**

August 2013				
United States of America	36.4	United Kingdom	3.8	
Europe	28.2	Hong Kong	2.7	
Japan	14.5	Australia	0.1	
South Africa	14.3	Canada	0.0	

### PERFORMANCE AND COMMENTARY

#### RETURNS SINCE INCEPTION (after fees)




### **RETURNS TO END AUGUST 2013\***

	Fund	Benchmark
1 Year (Class B)	18.5%	18.3%
3 Years	13.6%	14.0%
5 Years	9.8%	4.7%
Since Inception (Class B)	10.8%	9.0%
Maximum Drawdown**	-10.4%	-19.4%

- Returns are in USD net of fees with distributions re-invested. Source: RE:CM Analyst, Bloomberg.
- Periods greater than 1 year are annualised.
  Inception Date, 31 March 2006 (Class A), 14 December 2010 (Class B).
- \* Class A performance is provided in the table above unless indicated, to show historical performance as the B Class has only been operative since December 2010.
- \*\* Life of Fun

## **ASSET ALLOCATION**



### INVESTMENT COMMENT

Johnson & Johnson was one of the largest holdings in the Fund just over a year ago, but is now a small position. The pharmaceutical sector as a whole has been one of the prime beneficiaries of the flight to quality and yield that has occurred over the past two years. This has driven the share price of Johnson & Johnson to levels that are no longer nearly as attractive as they were even a year ago. Two years ago, there were grave concerns about the impact of a series of product defects in Johnson & Johnson's medical devices business (specifically in artificial hips) on the long-term future of the group. Today those concerns are all but forgotten by the market. The Fund retains its diversified exposure to a variety of leading global pharmaceutical companies, but the exposure is reducing. Tokyo Gas, the Japanese gas distribution business, has featured as a substantial holding in the Fund for a long time. Following the dramatic monetary policy easing announcements in Japan at the end of 2012, most of the Japanese stock market experienced a substantial rerating. The rising tide also lifted Tokyo Gas' share price, to the point where the Fund now has a very small exposure to this business. In a similar vein, we sold the last of the Fund's shares in Familymart, the Japanese convenience store operator, as its share price reached fair value in the short but dramatic Japanese bull market of the past several months.

Tel: +27 21 657 3440 Fax: +27 21 674 1088 Email: info@recm.co.za Website: www.recm.co.za